BET bromodomain inhibition as a novel strategy for reactivation of HIV-1 - Wikidata - awgldk - TriplyDB

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1

http://www.wikidata.org/entity/Q34032827

about

Structural insights into recognition of acetylated histone ligands by the BRPF1 bromodomain Epigenetic control of HIV-1 post integration latency: implications for therapy Impact of Chromatin on HIV Replication Manipulation of the host protein acetylation network by human immunodeficiency virus type 1 Bromodomain proteins in HIV infection The bromodomain: from epigenome reader to druggable target Recent developments in human immunodeficiency virus-1 latency research Protein lysine acetylation by p300/CBP Emerging strategies to deplete the HIV reservoir Targeting NF-κB signaling with protein kinase C agonists as an emerging strategy for combating HIV latency Targeting the Brain Reservoirs: Toward an HIV Cure Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents Brd4 activates P-TEFb for RNA polymerase II CTD phosphorylation The mechanisms behind the therapeutic activity of BET bromodomain inhibition An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression BET bromodomain proteins and epigenetic regulation of inflammation: implications for type 2 diabetes and breast cancer.Drug Discovery Targeting Bromodomain-Containing Protein 4.Rabies Virus Infection Induces Microtubule Depolymerization to Facilitate Viral RNA Synthesis by Upregulating HDAC6.Kaposi's sarcoma-associated herpesvirus ORF45 mediates transcriptional activation of the HIV-1 long terminal repeat via RSK2.Chemical probes targeting epigenetic proteins: Applications beyond oncology.Mechanism and factors that control HIV-1 transcription and latency activation BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma Molecular mechanisms of retroviral integration site selection.BET bromodomains mediate transcriptional pause release in heart failure BET bromodomain inhibitors: a patent review.[1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains Progress towards an HIV cure: update from the 2014 International AIDS Society Symposium Viral-host interactions that control HIV-1 transcriptional elongation BET bromodomain proteins are required for glioblastoma cell proliferation.RNA sequencing reveals distinct mechanisms underlying BET inhibitor JQ1-mediated modulation of the LPS-induced activation of BV-2 microglial cells Selective HDAC inhibition for the disruption of latent HIV-1 infection.Eradication of HIV-1 from the macrophage reservoir: an uncertain goal?Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.BET Bromodomain Proteins Brd2, Brd3 and Brd4 Selectively Regulate Metabolic Pathways in the Pancreatic β-Cell.Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk.BET-Inhibitors Disrupt Rad21-Dependent Conformational Control of KSHV Latency Altered regulation and expression of genes by BET family of proteins in COPD patients Dual transcriptome sequencing reveals resistance of TLR4 ligand-activated bone marrow-derived macrophages to inflammation mediated by the BET inhibitor JQ1.Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein

P2860

Q24305108-942747F9-2B1E-42B2-95D3-E1C89B3880E6 Q26781191-B95E4157-E1D0-47AA-B289-68CEE27F1D45 Q26782046-509E9A12-0C8B-4C14-BA9E-D837548D73DB Q26795463-04A41ED4-6CC0-4425-946B-F6E7D9FD50D6 Q26829860-E319A103-821F-4084-8A59-65E91055781A Q26999935-9A836BFC-983E-4485-9775-AFA8AC74597D Q27013114-07E0E54E-C367-4025-ABAA-43F677CF89E4 Q27021749-089A1408-E4AA-4491-9FE0-0CF9FBFA06A8 Q27023877-530B070F-3C5B-40F8-8D0E-6B45D74E3D56 Q27026631-6C367883-EDC6-4C8A-9660-E98F4F3ACB4F Q28075694-B9F23E48-9AB3-4299-82A2-D95A6491C96E Q28079455-B6E01E2B-9387-475F-8ADD-48D17A582BA1 Q28240747-3359C59D-0E83-4005-8EB5-82B5D26BE062 Q28241504-B0941CDF-BBE3-4F96-9DBF-8B6EED04999F Q28546918-0F34F6F5-7832-46C7-941E-A8CD67CE797A Q30248629-A3342A57-B456-44ED-9287-7060B89F3127 Q30352390-966BF9CF-DF48-4550-9EC0-377984F8FEF9 Q33603289-1D47E7DB-CC85-46E4-A24F-0D8F2F6ACD3D Q33743857-EF411494-8944-41C7-A9A9-CC70C9A8D256 Q33751386-612D8F03-BCB5-4889-AB0D-62BCF451A2D1 Q33826920-281B8152-FBCC-4DA9-A0D6-731C70E9303C Q33853887-F119457A-6E6E-412E-9832-44E594E4935E Q34249653-18EB5A73-5774-4500-96DF-035A09D42722 Q34361491-07147199-B7BF-4D0B-B349-69A53467B092 Q34386777-63FA322D-D50E-4CD4-8531-F09C2211C917 Q34390229-EA602743-1A0E-4BFD-B13D-B39D70250A95 Q34869380-6D109243-505F-46BE-9C5A-7904D1C95DD5 Q35026881-1F09E35C-3873-43C8-A0DB-BA89EA43EC36 Q35086848-56270ED7-40E0-4938-8207-B006F7F1BE74 Q35176766-BBB256D2-0615-4CD4-95B5-3B0B477721A9 Q35227888-28146467-48AB-42CA-BDC4-02114311B9C8 Q35544355-9B92CB00-5589-4C3A-9078-A4576C7F16BC Q35720063-F8C4960C-844A-4E24-902E-E0D23B42243A Q35914266-E53D3226-ACAD-4D8C-9E2F-7EAF9BAE4FF0 Q35967957-DA68829A-6DC7-49EA-BA8E-D78465DD7F13 Q36012341-193468FB-11EC-42A6-BEFE-CD43F9122777 Q36255788-68D76461-C1C5-4411-B0B7-4D546D975F60 Q36293942-93436A78-2705-4249-AA79-58DF965EE768 Q36298080-BAB65684-1DBC-48EB-A2C7-29850BCF1141 Q36332978-D8F54144-AC38-4052-816A-14FA075EBB99

P2860

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1

http://www.wikidata.org/entity/Q34032827

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1

@ast

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1

@en

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1

@nl

type

label

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1

@ast

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1

@en

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1

@nl

prefLabel

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1

@ast

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1

@en

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1

@nl

P1433

Q34032827-AAC88FC8-3425-4810-9500-EC70577A5B93

P1476

Q34032827-27DC13A5-9879-4F1B-BC46-2394DE039182

P2093

Q34032827-2BE2717A-2799-4AB4-84A1-A4A253043FAA

Q34032827-7C57C342-6F59-4285-9DF2-2F8105F1583E

Q34032827-B2E6661D-5F71-4008-A8D8-2E57400C8F45

Q34032827-F8548D5B-4201-40EF-96B3-FDF1723EDEDC

P2860

Q34032827-01D4D491-A48E-4093-96A3-D55C906B2578

Q34032827-02A335ED-EA66-4920-81B6-9B0068305C04

Q34032827-0B31FAFE-549A-46E9-8A10-E8323D873FC2

Q34032827-0E0852AF-5C40-41F2-BD63-E2CA99FA203B

Q34032827-1326465E-0F1B-48ED-9532-2EF1802869D9

Q34032827-1F9AB09C-CFB6-4E46-AE13-2BE9784A47EE

Q34032827-274B5646-8E35-496E-8223-E5D3FC6B6A45

Q34032827-2929C421-D5AA-45AC-8F02-74830E68B99E

Q34032827-2CE64567-B504-4237-A833-ECD28A88D040

Q34032827-2D5017D8-73C3-45B1-B9A8-4B58C627B510

P304

Q34032827-DC1DE4AA-C329-4163-A9CF-AA64A1DC90E4

P31

Q34032827-1DFC4D60-6C94-484D-96D3-7D0143E9C242

P356

Q34032827-2A3F8E40-3294-4704-9472-5E20D73177B5

P433

Q34032827-C0BD17FA-F4B5-497B-A552-EF27DC281600

P478

Q34032827-65E48FF9-56DB-49B3-9D1F-967F1CB6D9DB

P50

Q34032827-25EA35DD-80E3-4262-A6F5-7216ECBA1CDB

Q34032827-50911857-8680-45DE-A325-1F4E9ABE25CD

Q34032827-CC7C7415-6CB1-494C-B647-58E49541D51D

Q34032827-D0439D58-9F58-4F15-B6DA-072022C3050C

Q34032827-FF1449B7-36F2-480F-AF45-18C752546B83

P577

Q34032827-D09E3E8A-6A4B-45F4-A179-3CD871725693

P5875

Q34032827-F94E94EC-5566-4CE4-B2F7-5DE4CCAB1E63

P698

Q34032827-B732592B-66FD-4239-BBBA-4B7B044AB808

P932

Q34032827-C84BBA3C-BB86-4210-9882-099C6E9958E8

P356

P1433

Journal of Leukocyte Biology

P1476

BET bromodomain inhibition as a novel strategy for reactivation of HIV-1

@en

P2093

Camellia Banerjee

http://www.w3.org/2001/XMLSchema#string

Daniel Michaels

http://www.w3.org/2001/XMLSchema#string

James Bradner

http://www.w3.org/2001/XMLSchema#string

Nancie Archin

http://www.w3.org/2001/XMLSchema#string

P2860

Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection

Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase.

Selective inhibition of BET bromodomains

Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA

The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1.

Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor

Identifying biological themes within lists of genes with EASE

Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat Interactions with both cyclin T1 and the Tat transactivation region

Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription

The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses

P304

1147-1154

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1189/JLB.0312165

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P50

David M. Margolis

Paola Sebastiani

P577

2012-07-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229156855

http://www.w3.org/2001/XMLSchema#string

P698

22802445

http://www.w3.org/2001/XMLSchema#string

P932

3501896

http://www.w3.org/2001/XMLSchema#string